Unleashing Sustainability Potential of Southeast Asia
| GRI Etf | USD 0.80 0.05 5.88% |
Under 59% of GRI Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding GRI Bio suggests that many traders are alarmed. GRI Bio's investing sentiment shows overall attitude of investors towards GRI Bio.
GRI |
NORTHAMPTON, MA ACCESSWIRE June 6, 2023 GRI CEO Eelco van der Enden is in the ASEAN region from 5-13 June for a series of high-level meetings with companies, regulators, policymakers and stakeho
Read at accesswire.com
 |
GRI Bio Fundamental Analysis
We analyze GRI Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GRI Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GRI Bio based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
GRI Bio is currently under evaluation in probability of bankruptcy as compared to similar ETFs. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
GRI Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GRI Bio etf to make a market-neutral strategy. Peer analysis of GRI Bio could also be used in its relative valuation, which is a method of valuing GRI Bio by comparing valuation metrics with similar companies.
Peers
GRI Bio Related Equities
| PASG | Passage Bio | 2.63 | ||||
| CCCC | C4 Therapeutics | 1.39 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.72 | ||||
| IKNA | Ikena Oncology | 0.60 | ||||
| CELC | Celcuity LLC | 0.71 | ||||
| AVTE | Aerovate Therapeutics | 1.17 | ||||
| EWTX | Edgewise Therapeutics | 1.88 | ||||
| GBIO | Generation Bio | 2.52 | ||||
| CNTB | Connect Biopharma | 2.61 | ||||
| GLUE | Monte Rosa | 2.95 | ||||
| HOWL | Werewolf Therapeutics | 3.51 | ||||
| STTK | Shattuck Labs | 5.00 | ||||
| XLO | Xilio Development | 5.83 | ||||
| HCWB | HCW Biologics | 7.69 | ||||
| DSGN | Design Therapeutics | 8.79 | ||||
| PRLD | Prelude Therapeutics | 10.11 | ||||
| CUE | Cue Biopharma | 10.48 |
Other Information on Investing in GRI Etf
GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.